200618-15-1

Basic information

• Product Name: 3-nitro-N-(2-(trifluoromethyl)phenyl)benzamide
• Synonyms: 3-nitro-N-(2-(trifluoromethyl)phenyl)benzamide
• CAS NO: 200618-15-1
• Molecular Weight: 310.232
• Mol File: 200618-15-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-nitro-N-(2-(trifluoromethyl)phenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-N-(2-(trifluoromethyl)phenyl)benzamide(200618-15-1)
• EPA Substance Registry System: 3-nitro-N-(2-(trifluoromethyl)phenyl)benzamide(200618-15-1)

Safety Data

• Hazardous Substances Data: 200618-15-1(Hazardous Substances Data)

Upstream product

• 121-90-4 m-nitrobenzoic acid chloride 
• 88-17-5 2-(trifluoromethyl)benzenamine 

Downstream Products

• 897594-63-7 C₁₄H₁₁F₃N₂O 

Relevant articles and documents

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.